Japan
It will be used to accelerate collaborations with pharmaceutical firms.
Also, CureApp is getting $77 million in investment from the Sawai Group as part of their license deal.
The new funds will be used to support the rollout of its hypertension DTx app.
There is a plan to expand its trial to more ambulances in the country to study its effectiveness.
They will deliver connected caps for insulin and titration alerts to Japanese healthcare providers and patients.
They plan to release their digital solutions for insurance companies next year.
The study will accumulate objective lifestyle data from around 2,000 participants.
They aim to bring down the period and costs for new drug development.
The clearance represents what could be the world's first regulatory approval of a DTx app for hypertension treatment.
The AI tech can spot signs of pancreatic cancer from non-contrast CT images.